Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Arrowhead Pharmaceuticals ( (ARWR) ).
On September 11, 2025, Ionis Pharmaceuticals filed a patent infringement lawsuit against Arrowhead Pharmaceuticals, alleging that Arrowhead’s planned commercialization of the investigational drug plozasiran infringes on Ionis’s U.S. Patent No. 9,593,333. This legal action follows Arrowhead’s own filing on September 10, 2025, seeking a declaratory judgment that the patent is invalid and not infringed. The outcome of this legal dispute could significantly impact Arrowhead’s operations and its position in the market for treatments targeting familial chylomicronemia syndrome (FCS), as well as its stakeholders.
The most recent analyst rating on (ARWR) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on Arrowhead Pharmaceuticals stock, see the ARWR Stock Forecast page.
Spark’s Take on ARWR Stock
According to Spark, TipRanks’ AI Analyst, ARWR is a Neutral.
Arrowhead Pharmaceuticals’ overall stock score is primarily impacted by its challenging financial performance, which is a significant risk factor. However, strong technical indicators and positive corporate events, such as the Novartis partnership, provide some optimism. The valuation remains a concern due to negative earnings, but the earnings call suggests potential for future growth through strategic initiatives.
To see Spark’s full report on ARWR stock, click here.
More about Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals operates in the biotechnology industry, focusing on the development of RNA interference-based therapeutics. The company is involved in creating treatments for diseases with significant unmet medical needs, with a particular emphasis on genetic disorders.
Average Trading Volume: 2,286,486
Technical Sentiment Signal: Buy
Current Market Cap: $4.11B
For a thorough assessment of ARWR stock, go to TipRanks’ Stock Analysis page.